Status:
COMPLETED
Glucose Control Using 1,5-AG Testing
Lead Sponsor:
Qure Healthcare, LLC
Collaborating Sponsors:
GlycoMark, Inc.
Conditions:
Diabetes
Eligibility:
All Genders
Phase:
NA
Brief Summary
Glycemic excursions (temporary increases in blood glucose) are associated with health complications. Standard tests for diabetes (e.g. random blood sugar and HbA1c) do not test for these excursions de...
Detailed Description
Nearly half of the adult population, 114 million Americans, are diagnosed with diabetes or pre-diabetes, making it one of the most important public and personal health problems. Diabetes is the 7th le...
Eligibility Criteria
Inclusion
- A minimum of 2 years post residency but no more than 30 years in practice
- Board-certified in internal medicine or family practice, primary care physicians
- In a private solo or multi-group practice
- Minimum threshold of patients (40+) currently seen weekly
- A minimum of 15% of their panel under their care for diabetes
- Have not used GlycoMark assay in the past
- Informed, signed and voluntarily consented to be in the study
Exclusion
- Not board certified in their respective area of care
- Academic-based practice
- Have practiced as a board-certified physician for less than 2 or greater than 30 years
- Have used the GlycoMark assay
- Follow \<40 patients weekly
- \< 15% of their patient panel under their care for diabetes
- Non-English speaking
- Unable to access the internet
Key Trial Info
Start Date :
November 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2019
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT03765164
Start Date
November 5 2018
End Date
February 24 2019
Last Update
October 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QURE Healthcare
San Francisco, California, United States, 94109